Abstract
As gene therapy has matured from clinical trials to the first commercial products, understanding of the mechanisms of gene delivery has increased tremendously. This has also been reflected in viral vector development, creating a number of new approaches to tackle issues in transduction efficiency, biodistribution and viral safety. This review will highlight the most important issues and advancements in vector development, administration, surface modification, integration to host genome and safety. The gene therapy products currently available or near market approval, based on p53 expression (Gendicine™ and Advexin™), conditionally replicative adenoviruses (Oncorine™) and thymidine kinase + ganciclovir therapy (Cerepro®), are introduced with emphasis on the molecular mechanisms of action.
Keywords: Adenovirus, p53, conditional replication, thymidine kinase
Current Molecular Pharmacology
Title: Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Volume: 1
Author(s): J. K. Raty, J. T. Pikkarainen, T. Wirth and S. Yla-Herttuala
Affiliation:
Keywords: Adenovirus, p53, conditional replication, thymidine kinase
Abstract: As gene therapy has matured from clinical trials to the first commercial products, understanding of the mechanisms of gene delivery has increased tremendously. This has also been reflected in viral vector development, creating a number of new approaches to tackle issues in transduction efficiency, biodistribution and viral safety. This review will highlight the most important issues and advancements in vector development, administration, surface modification, integration to host genome and safety. The gene therapy products currently available or near market approval, based on p53 expression (Gendicine™ and Advexin™), conditionally replicative adenoviruses (Oncorine™) and thymidine kinase + ganciclovir therapy (Cerepro®), are introduced with emphasis on the molecular mechanisms of action.
Export Options
About this article
Cite this article as:
Raty K. J., Pikkarainen T. J., Wirth T. and Yla-Herttuala S., Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications, Current Molecular Pharmacology 2008; 1 (1) . https://dx.doi.org/10.2174/1874467210801010013
DOI https://dx.doi.org/10.2174/1874467210801010013 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genomic Organization and Control of the Grb7 Gene Family
Current Genomics Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy
Current Gene Therapy Edema-mass Ratio Based On Magnetic Resonance Imaging As A Preoperative Diagnostic Factor For Posterior Fossa Metastasis
Current Medical Imaging Skin as a Novel Route for Allergen-specific Immunotherapy
Current Pharmaceutical Design Mn-SOD and Chronic Inflammation of Gastric Mucosa
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design Silicosis in Current Scenario: A Review of Literature
Current Respiratory Medicine Reviews Effect of Dasatinib on Genes Related to Mitotic Catastrophe Pathway in Chronic Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design High Diagnostic and Prognostic Value of miRNAs Compared with the Carcinoembryonic Antigen As A Traditional Tumor Marker
Anti-Cancer Agents in Medicinal Chemistry